ADDvise signs Letter of Intent to acquire Medisuite, LLC

24-05-2021   Regulatory press release

ADDvise Group AB (publ) has signed a Letter of Intent with the shareholders of Medisuite, LLC (”Medisuite”) regarding an acquisition of 100 percent of the shares in Medisuite.

Medisuite is an American online pharmacy that specializes in medication for men’s health. The prescription medication that is marketed by Medisuite is mainly used for treatment of cancer, incontinence, and impotence. Medisuite’s customers are mainly physicians within the urology and oncology therapeutic areas.

Medisuite is headquartered in Cary, North Carolina. The company’s revenue for the financial year 2020 amounted to USD 3.04 million, the adjusted EBITDA to USD 1.45 million and the EBITDA-margin to 48%.

The purchase price amount totals USD 10.30 million, divided into an initial payment of USD 6.50 million, a two-year interest free promissory note of USD 1.30 million, and two potential earn-outs of a maximum of USD 2.50 million. The earn-outs are subject to the company achieving the 2022 and 2023 forecasts. The acquisition is financed through own funds and loan. ADDvise assess that the acquisition will have a positive effect on its earnings per share during the financial year 2021.

The acquisition is subject to ADDvise’s due diligence, and that the parties will agree to enter into a share purchase agreement. The share purchase agreement is scheduled to be completed during Q2 2021 and the acquisition is scheduled to be completed during Q3 2021.

For further information, please contact:

Rikard Akhtarzand, VD
+46 765-25 90 71

Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on 24 May 2021 at 08:20 CEST.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50,, is the Company's Certified Adviser. Additional information is available at

Latest press releases

ADDvise receives allocation decision worth approximately EUR 5 million


ADDvise Group AB (publ)’s subsidiary Sonar Oy has received an allocation decision from Oulu University Hospital in Finland regarding a long-term partnership for delivery of x-ray equipment and services during a ten-years period, with a total value of EUR 5 million. First installations are expected to take place during the year 2023. In accordance with…

ADDvise acquires Southern Life Systems, Inc.


ADDvise Group AB has today entered into a share purchase agreement with the owners of Sothern Life Systems, Inc. (“SLS”) regarding the acquisition of all shares of SLS in accordance with the letter of intent communicated via a press release dated August 30, 2021. Closing of the acquisition takes place today. SLS’ revenue for the…

ADDvise Group appoints interim CFO


ADDvise Group AB appoints Bengt Miller as interim Chief Financial Officer (CFO) and temporary member of the management team. He succeeds the current CFO, Aaron Wong, and will assume the role on 29 November 2021 until the 28[th] of February 2022 when the newly appointed CFO, Sebastian Robson, as previously communicated, commences his employment. Bengt…

ADDvise receives order worth USD 530,000


ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Masarat in Saudi Arabia, a company providing biosafety- and cleanroom services. The order is worth approximately USD 530,000 and involves design and construction of a cleanroom facility for the manufacturing of surgical sutures for Advanced Bio-Medical Industrial Co in Saudi Arabia. Delivery of…